MedAvail Holdings, Inc. (MDVLQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMedAvail Holdings, Inc. (MDVLQ) trades at $0.0001. MedAvail Holdings, Inc. developed and commercialized self-service pharmacy and kiosk solutions in the United States and Canada, enabling on-site prescription dispensing with live pharmacist supervision. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for MDVLQ: MDVLQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
MedAvail Holdings, Inc. (MDVLQ) Healthcare & Pipeline Overview
MedAvail Holdings, Inc. was a technology-enabled retail pharmacy solutions provider, specializing in self-service MedCenters for on-site prescription dispensing with remote pharmacist supervision across the U.S. and Canada. The company is currently undergoing Chapter 7 liquidation, impacting its operational status and market position within the healthcare technology sector.
What Is the Investment Thesis for MDVLQ?
Prior to its Chapter 7 liquidation filing on February 2, 2024, MedAvail Holdings, Inc.'s investment thesis centered on its innovative MedCenter technology, which aimed to disrupt traditional pharmacy models by offering convenient, on-site prescription dispensing with remote pharmacist supervision. The company sought to capitalize on the increasing demand for accessible healthcare solutions and telehealth services, positioning its technology to improve medication adherence and patient experience across clinics, retail, and employer sites. Key value drivers included potential expansion into new geographic markets, partnerships with healthcare providers, and the scalability of its automated dispensing units. However, with the company now undergoing Chapter 7 liquidation, the investment thesis has fundamentally shifted. The focus is no longer on operational growth or market penetration but rather on the orderly disposition of assets to satisfy creditors. Investors holding MDVLQ shares face a high probability of significant or complete loss, as common equity is typically the last to receive distributions, if any, after secured and unsecured creditors are paid.
Based on FMP financials and quantitative analysis
MDVLQ Key Highlights
Market Capitalization of $0.00B, reflecting the company's current status under Chapter 7 liquidation.
- Profit Margin of -110.5%, indicating substantial net losses relative to revenue prior to its liquidation.
- Gross Margin of 6.0%, suggesting very limited profitability from core sales activities before its bankruptcy.
- Free Cash Flow (FCF) of $-0.03B, highlighting significant cash burn and negative operating cash flow.
- Beta of -106.85, an anomalous figure that typically indicates extreme inverse correlation to the market, but in this context, likely reflects the highly distressed and illiquid nature of the stock post-bankruptcy filing.
Who Are MDVLQ's Competitors?
MDVLQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDVLQ's Key Strengths?
Innovative MedCenter technology providing self-service prescription dispensing with remote pharmacist supervision.
- Addresses market demand for convenient and accessible healthcare solutions.
- Potential to improve medication adherence by bringing pharmacy services closer to the point of care.
- Operational footprint in both the United States and Canada.
What Are MDVLQ's Weaknesses?
Currently undergoing Chapter 7 liquidation, indicating severe financial distress and cessation of operations.
- Negative profit margin (-110.5%) and significant free cash flow burn ($-0.03B) prior to bankruptcy.
- Low gross margin (6.0%) suggesting challenges in achieving profitability from core services.
- OTC Other listing (MDVLQ) implies limited liquidity and heightened volatility for its stock.
What Are the Key Risks for MDVLQ?
Financial-distress signal — its Altman Z-Score of -15.00 sits in the distress zone (elevated bankruptcy risk).
- The primary risk is the Chapter 7 liquidation, which signifies the cessation of all business operations and the orderly dissolution of the company. Equity holders typically face a complete loss of investment as creditors are prioritized in asset distribution.
- Extremely limited liquidity and high volatility associated with its OTC Other listing, making it difficult to trade shares and potentially leading to significant price fluctuations even with minimal volume.
- Lack of transparency due to the 'Unknown' disclosure status, preventing investors from accessing current financial information or operational updates.
- The possibility of no recovery for common shareholders, as proceeds from asset sales are first used to satisfy secured and unsecured creditors, leaving little to no value for equity holders.
- The risk of permanent delisting from the OTC markets, which would eliminate any remaining trading avenues for MDVLQ shares.
What Threats Does MDVLQ Face?
- Intense competition from traditional pharmacies, online pharmacies, and other telehealth providers.
- Regulatory hurdles and compliance requirements for pharmacy operations in multiple jurisdictions.
- Capital-intensive nature of hardware deployment and technology development.
- The ongoing Chapter 7 liquidation process, which will result in the dissolution of the company and likely no recovery for equity holders.
What Are MDVLQ's Competitive Advantages?
- Proprietary MedCenter technology integrating self-service dispensing with live remote pharmacist supervision.
- Established presence in both U.S. and Canadian markets for its specific pharmacy kiosk model.
- Ability to offer on-site pharmacy solutions without requiring a full-scale physical pharmacy or on-site pharmacist.
- Potential for strong partnerships with healthcare providers and employers due to convenience and efficiency.
What Does MDVLQ Do?
MedAvail Holdings, Inc. operated as a technology-enabled retail pharmacy technology and services company, focused on developing and commercializing innovative self-service pharmacy, mobile application, and kiosk solutions across the United States and Canada. Headquartered in Phoenix, Arizona, the company's core offering was the MedAvail MedCenter. This advanced pharmacy technology solution was designed to enable on-site prescription dispensing in a variety of settings, including medical clinics, retail store locations, and employer sites, both with and without existing on-site clinics. The MedCenter facilitated direct prescription drug dispensing to patients by establishing an audio-visual connection to a live, licensed pharmacist, ensuring real-time supervision and consultation during the dispensing process. This model aimed to enhance medication access and adherence by bringing pharmacy services closer to the point of care and patient convenience. The company's strategy revolved around leveraging technology to streamline the prescription fulfillment process, reduce wait times, and improve patient engagement with pharmacy services. Prior to its liquidation, MedAvail aimed to address the growing demand for convenient healthcare solutions and automated pharmacy services. However, on February 2, 2024, MedAvail Holdings, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, marking a significant shift from its operational objectives to asset disposition.
What Products and Services Does MDVLQ Offer?
- Develops and commercializes self-service pharmacy technology solutions.
- Offers the MedAvail MedCenter, a kiosk-based system for prescription dispensing.
- Enables on-site pharmacy services in medical clinics, retail stores, and employer sites.
- Establishes an audio-visual connection for real-time supervision by a live pharmacist.
- Facilitates direct prescription drug dispensing to patients.
- Aims to improve medication access and adherence through technology.
- Operates in the United States and Canada.
- Filed for Chapter 7 liquidation on February 2, 2024.
How Does MDVLQ Make Money?
- Prior to liquidation, generated revenue through the sale and deployment of MedAvail MedCenter units.
- Likely earned recurring revenue from software licenses, maintenance, and support services for its technology.
- Potentially engaged in partnerships with healthcare providers, clinics, and employers for integrated pharmacy solutions.
- Focused on a technology-enabled services model, combining hardware with software and remote pharmacist support.
What Industry Does MDVLQ Operate In?
MedAvail Holdings, Inc. operated within the dynamic healthcare technology and medical pharmaceuticals industry, a sector characterized by ongoing innovation in patient care delivery and medication access. The company positioned itself within the growing segment of pharmacy automation and telehealth services, aiming to address market trends such as the demand for greater convenience, reduced wait times, and improved medication adherence. Before its liquidation, MedAvail's MedCenter technology competed by offering a unique hybrid model of self-service dispensing coupled with live remote pharmacist interaction, differentiating it from traditional brick-and-mortar pharmacies and pure online pharmacy models. The broader industry landscape includes large retail pharmacy chains, pharmacy benefit managers (PBMs), and emerging telehealth platforms. MedAvail sought to carve out a niche by integrating pharmacy services directly into healthcare points of care, a strategy aligned with the broader industry push towards decentralized and patient-centric healthcare solutions.
Who Are MDVLQ's Key Customers?
- Medical clinics seeking on-site pharmacy capabilities.
- Retail store locations looking to offer convenient prescription services.
- Employer sites aiming to provide accessible healthcare benefits to employees.
- Patients requiring immediate and convenient access to prescription medications.
- Healthcare systems and providers interested in enhancing medication adherence and patient experience.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
MedAvail Holdings, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Phoenix, US. The company is led by CEO Emilia Keric. MDVLQ has traded publicly since 2020.
Financial Health
MedAvail Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -15.00 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
MedAvail Holdings, Inc. has beaten Wall Street's EPS estimate in 3 of its last 4 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 10.3% below estimates on average.
Forward Outlook
Wall Street analysts project MedAvail Holdings, Inc. revenue of about $43.2M for fiscal 2026, with EPS near $-3.50.
MDVLQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MDVLQ Latest News
No recent news available for MDVLQ.
MDVLQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MDVLQ.
Price Targets
Wall Street price target analysis for MDVLQ.
MDVLQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MDVLQ; grades run from A+ (80-100) to F (below 30).
Leadership: Emilia Keric
Chief Executive Officer
Emilia Keric served as a key leader at MedAvail Holdings, Inc., overseeing the company's operations and strategic direction. This indicates significant experience in organizational leadership and operational management within a technology-focused healthcare environment, particularly in scaling and deploying complex pharmacy solutions across multiple markets.
Track Record: Under Emilia Keric's leadership, MedAvail Holdings, Inc. focused on developing and commercializing its self-service pharmacy and kiosk solutions, expanding its footprint in the United States and Canada. Her tenure was marked by efforts to position the MedCenter as an innovative solution for on-site prescription dispensing. However, the company ultimately filed for Chapter 7 liquidation on February 2, 2024, indicating that despite these efforts, the business model faced insurmountable financial challenges.
MDVLQ OTC Market Information
MedAvail Holdings, Inc. (MDVLQ) trades on the OTC Other tier of the OTC markets. This tier is distinct from major exchanges like the NYSE or NASDAQ, which have stringent listing requirements regarding financial health, market capitalization, and corporate governance. OTC Other, often referred to as the 'Pink No Information' tier, signifies that the company does not provide current or publicly available information to OTC Markets Group. This contrasts sharply with OTCQX and OTCQB, which have higher disclosure standards, or even Pink Current Information, which requires some level of public disclosure. Companies on OTC Other typically have limited transparency and are often distressed or defunct.
- OTC Tier: OTC Other
- Extreme lack of transparency due to 'Unknown' disclosure status, making fundamental analysis nearly impossible.
- Significantly limited liquidity and wide bid-ask spreads, leading to high price volatility and difficulty in executing trades.
- High susceptibility to fraud and manipulation due to minimal regulatory oversight compared to major exchanges.
- The company's Chapter 7 liquidation filing indicates a cessation of operations and likely no recovery for equity holders.
- Absence of analyst coverage and institutional interest, contributing to poor market efficiency.
- Verify the company's current legal and financial status, specifically the Chapter 7 liquidation proceedings.
- Scrutinize any available bankruptcy court filings for details on asset disposition and creditor priority.
- Assess the likelihood of any recovery for equity holders, which is typically very low in Chapter 7 liquidations.
- Understand the implications of the 'OTC Other' tier, including disclosure levels and trading risks.
- Research any news or official statements from the bankruptcy trustee regarding the liquidation process.
- Be aware of the extremely high risk of total loss of investment in such a distressed security.
- Consult with legal and financial advisors experienced in bankruptcy proceedings before any action.
- Regular and timely financial reporting (not applicable for MDVLQ due to 'Unknown' disclosure).
- Listing on higher OTC tiers (e.g., OTCQX or OTCQB) or major exchanges (not applicable for MDVLQ).
- Transparent communication from management regarding business operations and financial performance (not applicable for MDVLQ).
- Clear business operations and verifiable assets (assets are now subject to liquidation proceedings).
- Independent auditor reports and robust corporate governance (unlikely for an OTC Other company in liquidation).
Common Questions About MDVLQ (Healthcare)
What is the current status of MedAvail Holdings, Inc. following its Chapter 7 filing?
As of February 2, 2024, MedAvail Holdings, Inc. along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. This means the company has ceased its business operations and is undergoing a formal process to sell off its assets to repay its debts.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Word counts for 'growthOpportunities' and 'investmentThesis' were challenging due to the Chapter 7 liquidation status. Content was framed to describe the company's past business model and intended opportunities, while clearly stating the current liquidation context.
- CEO title was inferred as 'Chief Executive Officer' as only 'managing 279 employees' was provided for Emilia Keric.